EE498 Economic Evaluation of Nanoparticle Albumin-Bound paclitaxel for Previously Treated Advanced NSCLC in Japan
This study aimed to assess the cost-effectiveness of nab-paclitaxel compared with docetaxel from the Japanese payer ’s perspective. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: Y. Fukui, W. Chen, T. Maeda, K. Morimoto, K. Moriwaki, K. Shimozuma Source Type: research
Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer
CONCLUSION: Survival is significantly improved in those downstaged, as assessed by the CAP Tumor Regression Schema. Downstaging is an important prognostic variable that can help with joint decision making for clinicians and patients.PMID:37227766 | DOI:10.1177/00031348231175120 (Source: The American Surgeon)
Source: The American Surgeon - May 25, 2023 Category: Surgery Authors: Laura M Nicolais Molly Caron Nicholas Verdini Timothy L Fitzgerald Source Type: research
Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer
CONCLUSION: Survival is significantly improved in those downstaged, as assessed by the CAP Tumor Regression Schema. Downstaging is an important prognostic variable that can help with joint decision making for clinicians and patients.PMID:37227766 | DOI:10.1177/00031348231175120 (Source: The American Surgeon)
Source: The American Surgeon - May 25, 2023 Category: Surgery Authors: Laura M Nicolais Molly Caron Nicholas Verdini Timothy L Fitzgerald Source Type: research
A small-scale, exploratory real-world study of nab-paclitaxel combined with oxaliplatin and tegafur in the perioperative treatment of advanced gastric cancer: a study protocol for a real-world clinical trial
DISCUSSION: Based on the findings of previous studies, we wished to assess the safety and efficacy of nab-paclitaxel combined with LBP and tegafur in the treatment of advanced gastric cancer. The trial requires constant contact and monitoring. The purpose is to determine a superior protocol in terms of patient survival, and pathological and objective response.TRIAL REGISTRATION: This trial has been registered with the Clinical Trial Registry: NCT05052931 (registration date: 2021/9/12).PMID:37201078 | PMC:PMC10186493 | DOI:10.21037/jgo-23-131 (Source: Cancer Control)
Source: Cancer Control - May 18, 2023 Category: Cancer & Oncology Authors: Jiyang Zheng Shu Wang Guanghui Xu Juan Wang Yuhao Wang Jialin Luo Yan Wang Jianjun Yang Source Type: research
Myelosuppression caused by nanoparticle albumin-bound paclitaxel in the Northern Chinese population and the role of body composition
This article is protected by copyright. All rights reserved.PMID:37128692 | DOI:10.1002/jcph.2259 (Source: The Journal of Clinical Pharmacology)
Source: The Journal of Clinical Pharmacology - May 2, 2023 Category: Drugs & Pharmacology Authors: Yongzhi Shi Jiayuan Guo Ying Jiang Juan Zhao Jiaxuan Li Jing Shen Gaowa Jin Xiaojun Bai Quanfu Li Source Type: research
Myelosuppression caused by nanoparticle albumin-bound paclitaxel in the Northern Chinese population and the role of body composition
This article is protected by copyright. All rights reserved.PMID:37128692 | DOI:10.1002/jcph.2259 (Source: The Journal of Clinical Pharmacology)
Source: The Journal of Clinical Pharmacology - May 2, 2023 Category: Drugs & Pharmacology Authors: Yongzhi Shi Jiayuan Guo Ying Jiang Juan Zhao Jiaxuan Li Jing Shen Gaowa Jin Xiaojun Bai Quanfu Li Source Type: research
Efficacy and safety of nanoparticle albumin ‐bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non‐small cell lung cancer: A multicenter Phase 2 clinical trial
ConclusionsNab-paclitaxel therapy improved ORR after PD-(L)1 inhibitor treatment failure with a durable response of 13% and acceptable toxicities in patients with advanced NSCLC. (Source: Cancer Medicine)
Source: Cancer Medicine - April 21, 2023 Category: Cancer & Oncology Authors: Tomoaki Sonoda,
Yukihiro Umeda,
Yoshiki Demura,
Toshihiko Tada,
Koki Nakashima,
Masaki Anzai,
Makiko Yamaguchi,
Akikazu Shimada,
Masahiro Ohi,
Chisato Honjo,
Yuko Waseda,
Masaya Akai,
Tamotsu Ishizuka Tags: RESEARCH ARTICLE Source Type: research
Preliminary report on the short-term efficacy and safety of SAPO-S1 therapy for locally advanced gastric cancer with a deep learning perspective
This study aimed to evaluate the efficacy of S1 chemotherapy regimen combined with multiple chemotherapy drugs sindilizumab (PD-1 inhibitor), albumin-bound paclitaxel and oxaliplatin) for neoadjuvant therapy in locally advanced Gastric Cancer (LA-GC). The patients were given 4 cycles of sindilizumab combined with albumin paclitaxel+oxaliplatin+S-1 chemotherapy (SAPO-S1) before surgery. The R0 resection rate, surgical complications, pathologic complete response, complete pathologic response (pCR) the main pathological response rates (residual tumor cells≤10%, major pathological response) were observed. MPR and postoperati...
Source: Cancer Control - April 20, 2023 Category: Cancer & Oncology Authors: Yecheng Lin Lei Zhang Xiaoling Zhang Xiaonan Wei Xu Liu Yanchao Xie Guoda Han Source Type: research
Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial
CONCLUSIONS: Nab-paclitaxel therapy improved ORR after PD-(L)1 inhibitor treatment failure with a durable response of 13% and acceptable toxicities in patients with advanced NSCLC.PMID:37081729 | DOI:10.1002/cam4.5978 (Source: Cancer Control)
Source: Cancer Control - April 20, 2023 Category: Cancer & Oncology Authors: Tomoaki Sonoda Yukihiro Umeda Yoshiki Demura Toshihiko Tada Koki Nakashima Masaki Anzai Makiko Yamaguchi Akikazu Shimada Masahiro Ohi Chisato Honjo Yuko Waseda Masaya Akai Tamotsu Ishizuka Source Type: research
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)
ConclusionsThe primary endpoint for PFS was statistically not met, but modification of nab-PTX plus RAM to a bi-weekly schedule might be a feasible treatment option as second-line treatment for advanced GC/GJC patients, especially elderly patients, with severe AEs during the first cycle. (Source: Targeted Oncology)
Source: Targeted Oncology - April 15, 2023 Category: Cancer & Oncology Source Type: research
Plasma Stability and Plasma Metabolite Concentration –Time Profiles of Oligo(Lactic Acid)8-Paclitaxel Prodrug Loaded Polymeric Micelles
AbstractPaclitaxel (PTX) is a frequently prescribed chemotherapy drug used to treat a wide variety of solid tumors. Oligo(lactic acid)8-PTX prodrug (o(LA)8-PTX) loaded poly(ethylene glycol)-b-poly(lactic acid) (PEG-b-PLA) micelles have higher loading, slower release and higher antitumor efficacy in murine tumor models over PTX-loaded PEG-b-PLA micelles. The goal of this work is to study plasma stability of o(LA)8-PTX-loaded PEG-b-PLA micelles and its pharmacokinetics after IV injection in rats. In rat plasma, o(LA)8-PTX prodrug is metabolized into o(LA)1-PTX and PTX. In human plasma, o(LA)8-PTX is metabolized more slowly i...
Source: The AAPS Journal - April 11, 2023 Category: Drugs & Pharmacology Source Type: research
The efficacy and safety of nanoparticle albumin bound-paclitaxel-based regimen as second- or third-line treatment in patients with advanced esophageal squamous cell carcinoma
CONCLUSIONS: Nab-paclitaxel-based regimen could be a safe and effective option as second- or later-line treatment in patients with advanced ESCC, regardless of their previous exposure to PD-1 inhibitors.PMID:37035870 | DOI:10.1111/1759-7714.14885 (Source: Cancer Control)
Source: Cancer Control - April 10, 2023 Category: Cancer & Oncology Authors: Dao Xin Yan Song Lan Mu Bo Zhang Ling Qi Jing Gao Xingyuan Wang Jianping Xu Tao Qu Jing Huang Source Type: research
